scholarly journals Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab

2020 ◽  
Vol Volume 13 ◽  
pp. 4385-4395 ◽  
Author(s):  
Ran Ran ◽  
Wenfa Huang ◽  
Yaxin Liu ◽  
Lin Shao ◽  
Xiaoran Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Copy Number ◽  
Prognostic Value ◽  
Gene Copy Number ◽  
Metastatic Breast ◽  
Gene Copy ◽  
First Line ◽  
Her2 Gene ◽  
Her2 Positive

Prognostic role of plasma HER2 gene copy number in patients with HER2 positive metastatic breast cancer.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e13018-e13018 ◽  
Author(s):  
Ran Ran ◽  
Wenfa Huang ◽  
Shao Lin ◽  
Yunyun Niu ◽  
Hope S. Rugo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Copy Number ◽  
Gene Copy Number ◽  
Metastatic Breast ◽  
Gene Copy ◽  
Prognostic Role ◽  
Her2 Gene ◽  
Her2 Positive

Correlation of efficacy between EGFR gene copy number and lapatinib/capecitabine therapy in HER2-positive metastatic breast cancer.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 1059-1059 ◽  
Author(s):  
A. Fabi ◽  
A. Di Benedetto ◽  
R. Merola ◽  
G. Metro ◽  
M. Mottolese ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Copy Number ◽  
Gene Copy Number ◽  
Metastatic Breast ◽  
Gene Copy ◽  
Her2 Positive ◽  
Egfr Gene

Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer

2013 ◽  
Vol 14 (6) ◽  
pp. 699-706 ◽  
Author(s):  
Alessandra Fabi ◽  
Roberta Merola ◽  
Gianluigi Ferretti ◽  
Anna Di Benedetto ◽  
Barbara Antoniani ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Copy Number ◽  
Receptor Gene ◽  
Gene Copy Number ◽  
Growth Factor Receptor ◽  
Metastatic Breast ◽  
Gene Copy ◽  
Her2 Positive ◽  
Epidermal Growth

scholarly journals An Open‐Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First‐Line HER2‐Positive Metastatic Breast Cancer

2013 ◽  
Vol 18 (6) ◽  
pp. 661-666 ◽  
Author(s):  
Francisco J. Esteva ◽  
Sandra X. Franco ◽  
Maura K. Hagan ◽  
Abenaa M. Brewster ◽  
Robert A. Somer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
First Line ◽  
Her2 Positive ◽  
Open Label ◽  
Safety Study

Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel inHER2-Positive Metastatic Breast Cancer

2010 ◽  
Vol 28 (6) ◽  
pp. 976-983 ◽  
Author(s):  
Andrew M. Wardley ◽  
Xavier Pivot ◽  
Flavia Morales-Vasquez ◽  
Luis M. Zetina ◽  
Maria de Fátima Dias Gaui ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Response Rate ◽  
Performance Status ◽  
Locally Advanced ◽  
Metastatic Breast ◽  
Progression Free Survival ◽  
First Line ◽  
Her2 Positive ◽  
Grade 3

PurposeTo evaluate trastuzumab (H) and docetaxel (T) with or without capecitabine (X) as first-line combination therapy for human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer.Patients and MethodsPatients with HER2-positive locally advanced or metastatic breast cancer were randomly assigned to H (8 mg/kg loading; 6 mg/kg every 3 weeks) plus T (75 mg/m2in HTX arm, 100 mg/m2in HT arm, every 3 weeks) with or without X (950 mg/m2twice per day on days 1 to 14 every 3 weeks). The primary end point was overall response rate (ORR).ResultsIn 222 patients, median follow-up was approximately 24 months. ORR was high with both regimens (70.5% with HTX; 72.7% with HT; P = .717); complete response rate was 23.2% with HTX compared with 16.4% with HT. HTX demonstrated significantly longer progression-free survival: median 17.9 months compared with 12.8 months with HT (hazard ratio, 0.72; P = .045), which translates to a gain of around 5 months. Two-year survival probability was 75% with HTX compared with 66% with HT. Febrile neutropenia (27% v 15%) and grade 3/4 neutropenia (77% v 54%) incidences were higher with HT than HTX. Treatment-related grade 3 hand-foot syndrome (17% v < 1%) and grade 3/4 diarrhea (11% v 4%) occurred more commonly with HTX than HT. One case of congestive heart failure occurred in each arm.ConclusionHTX is an effective and feasible first-line therapy for HER2-positive locally advanced or metastatic breast cancer, although it should be reserved for patients with good performance status who are not receiving long-term steroids.

Sign in / Sign up

Export Citation Format

Share Document